Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives

Research has shown that diabetes mellitus is not just a disorder of blood sugar, but a complex metabolic imbalance that also profoundly involves lipid metabolism. Patients with diabetes often show alterations in their lipid profile, which contribute to the risk of cardiovascular complications. The EmDia clinical trial, a randomized, placebo-controlled study, has investigated the impact of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on the plasma lipidome in patients with type 2 diabetes (T2DM). The goal was to identify molecular alterations that could explain the drug's cardiovascular and renal benefits, which extend beyond simple glucose reduction. Using an untargeted lipidomics approach and advanced statistical techniques like sparse group LASSO regression, the study identified significant and reproducible alterations in specific lipid classes, most notably lysophosphatidylcholines (LPCs), after one and twelve weeks of treatment. These changes in the lipid profile correlated with clinical parameters such as estimated glomerular filtration rate (eGFR), uric acid, and blood pressure, suggesting that LPCs could serve as biomarkers of drug response. The discovery of LPCs as potential markers of empagliflozin's effect opens new avenues for developing pharmacodynamic biomarkers and understanding the metabolic mechanisms of action, including the relationship between lipid metabolism and kidney health.